MedWatch

VP: Lundbeck first with new Alzheimer’s drug

New requirements from the FDA increases the probability of an approval of Lundbeck’s new candidate drug to treat Alzheimer’s as the next on the market. But rivals are waiting in the stands – especially drug giant Eli Lilly.

Foto: Lundbeck/PR

In spite of intense global competition, Lundbeck has a chance of becoming the first drug company in the world to launch a new drug to treat Alzheimer’s disease.

That is the definite conviction of Anders Gersel Pedersen VP of Research & Development in Lundbeck. It follows a recent announcement revealing that Lundbeck’s Japanese partner Otsuka is planning to test the potential Alzheimer’s treatment, Lu AE58054, in 3,000 patients in four global phase III studies – the final phase of testing prior to approval of a drug. Only a handful of drugs make the cut – and the next one to do so could well be Danish.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier